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Abstract
A 70-year-old man was admitted to our hospital with an abnormal chest X-
ray shadow. Bronchoscopy revealed an adenocarcinoma tumour with an
epidermal growth factor receptor (EGFR) exon 19 deletion. Positron emis-
sion tomography–computed tomography scanning and magnetic resonance
imaging showed advanced stage IV lung cancer. He was treated with erloti-
nib as a ﬁrst-line drug, which maintained a clinical response for 16 months.
After disease progression, a re-biopsy was done from the tumour in the
right lower lobe. The obtained specimen harboured both small-cell lung
cancer (SCLC) transformation with retention of the EGFR 19 deletion and
the development of an EGFR T790M mutation. We came across a very rare
condition of concomitant T790M mutation and SCLC transformation after
acquired resistance to EGFR-tyrosine kinase inhibitor.
Introduction
Although epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) drastically improves lung cancer with
the EGFR mutation, drug resistance after long-term use is
inevitable. The mechanisms underlying resistance have
recently become clearer [1,2]. T790M mutation and small-
cell lung cancer (SCLC) transformation are well known
mechanisms of EGFR-TKI resistance [1–3]. Recently, a
report showed a reciprocal relation between the SCLC trans-
formation and the EGFR T790M mutation [4]. We came
across a case of concomitant T790M mutation and SCLC
transformation after acquired resistance to EGFR-TKI.
Case Report
A 70-year-old man was admitted to our hospital with an
abnormal chest X-ray shadow in November 2013. Positron
emission tomography–computed tomography and mag-
netic resonance imaging showed a right lower-lobe mass
and multiple bone and brain metastases. Bronchoscopy
revealed an adenocarcinoma (Fig. 1A–C) with an EGFR
exon 19 deletion (E746-A750). His clinical stage was
T2aN2M1b (stage IV).
He was treated with erlotinib as a ﬁrst-line drug after
whole-brain irradiation, which maintained a clinical
response for 16 months. After disease progression was con-
ﬁrmed in April 2015, a re-biopsy was done from the
tumour in the right lower lobe to check the mechanism of
EGFR-TKI resistance. The obtained specimen harboured
both SCLC transformation (Fig. 2A, B) with retention of
the EGFR 19 deletion and the development of an EGFR
T790M mutation. Cytotoxic chemotherapy targeting SCLC
was selected for second-line therapy. He received six cycles
of chemotherapy until October 2015 and achieved a modest
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clinical response. After it was approved in May 2016, he
began receiving osimertinib continuously as the third-line
therapy, which has maintained a clinical response.
Discussion
Although most lung cancers harbouring EGFR mutations
achieve drastic response to treatment with EGFR-TKI,
developing drug resistance after long-term use is inevitable.
Recently, the mechanisms of resistance to EGFR-TKI are
becoming well known. Acquiring an EGFR T790M muta-
tion is a major cause of EGFR-TKI resistance [1,2]. An
EGFR T790M mutation is detected in about half of
patients who previously underwent EGFR-TKI treatment
[1,2]. Transformation to SCLC is another resistance
mechanism. It is observed in <20% of cases and is less
common than the EGFR T790M mutation [3].
It is known that EGFR-TKI-resistant patients often have
SCLC transformation and a sensitive EGFR mutation in
recurrent tumours [3]. This phenomenon suggests the
existence of a shared origin for cancer stem cells in the
tumours. It is also known that different resistance factors
have reciprocal relationships with each other [5]. Recently,
Suda et al. mentioned a reciprocal relationship between the
SCLC transformation and the EGFR T790M mutation [4].
Compared to these previous reports, our case was unique
for having different resistance mechanisms in the same
cancer cells. Because the treatment of erlotinib had main-
tained a response for 16 months and SCLC retaining the
EGFR exon 19 deletion was identiﬁed, the present case
Figure 1. First biopsy specimens showing malignant cells with irregular papillary and tubular structures (A, haematoxylin and eosin staining, ×100).
Immunohistopathological analysis demonstrated positive staining for thyroid transcription factor 1 (TTF-1) (B, ×400) and novel aspartic proteinase of
the pepsin family (napsin A) (C, ×400), which are markers of adenocarcinoma. Immunohistopathological analysis also demonstrated positive staining
for synaptophysin, which suggests neuroendocrine differentiation (D, ×400).
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was not likely to have had SCLC initially but suggested to
share the origin of cancer stem cells. In addition to having
initial morphological and immunohistological features of
adenocarcinoma, our case also showed positive staining of
synaptophysin, suggesting neuroendocrine differentiation
(Fig. 1D). Immunohistological speciﬁcity may inﬂuence
this unique result. Because we identiﬁed the T790M muta-
tion, we challenged osimertinib for our patient. Osimerti-
nib is the oral, third-generation EGFR-TKI, which is
designed to target the EGFR T790M mutation while spar-
ing wild-type EGFR. Phase I and II studies of osimertinib
have shown good clinical activity [6,7].
In conclusion, this is the ﬁrst case of concomitant
T790M mutation and SCLC transformation after a patient
acquired resistance to EGFR-TKI. Learning point from our
case is that it might be helpful to consider checking the
T790M mutation even when SCLC transformation is con-
ﬁrmed at re-biopsy. Compilation of more such cases and
further analysis of similar cases are required.
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Figure 2. Second biopsy (after acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance developed) specimens
showing diffuse proliferation of small- to intermediate-sized cells with scant cytoplasm and round to oval hyperchromatic nuclei. Immunohistopatho-
logical analysis demonstrated positive staining for synaptophysin (A, ×400) and chromogranin (B, ×400), which are markers of small-cell carcinoma.
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